Poolbeg Pharma Advances POLB 001 Cancer Therapy with FDA Approval and Canadian Patent
Key Insights
Poolbeg Pharma (search) received positive FDA feedback for POLB 001's development pathway, including agreement on the primary endpoint for a future phase III clinical trial.
The company secured a Canadian patent for POLB 001 covering the prevention of cancer (search) immunotherapy-induced cytokine release syndrome (search), marking the second national approval in its patent family.
POLB 001 is being developed as a preventative therapy for cytokine release syndrome (search), a potentially life-threatening immune overreaction triggered by cancer (search) immunotherapy treatments.
Poolbeg Pharma (search) PLC has achieved significant regulatory and intellectual property milestones for its lead cancer (search) therapy candidate POLB 001, receiving positive feedback from the US Food and Drug Administration (FDA) and securing a Canadian patent for the drug's use in preventing cytokine release syndrome (search) (CRS).
FDA Provides Development Pathway Clarity
The FDA's feedback during a pre-investigational new drug (IND) meeting was broadly aligned with key aspects of Poolbeg's proposed development strategy for POLB 001. The regulatory agency agreed on the primary endpoint for a future phase III clinical trial, providing crucial guidance for the drug's advancement through clinical development.
Bruno Speder, vice president of regulatory affairs at Poolbeg, said the company achieved broad alignment on several important aspects of the development pathway and that the feedback supports ongoing partnering discussions. The pre-IND meeting allows pharmaceutical companies to present their clinical development plans and receive regulatory guidance before formally submitting an application to begin human trials in the US.
Canadian Patent Strengthens IP Portfolio
Poolbeg secured a Canadian patent approval covering the use of POLB 001 in preventing cancer (search) immunotherapy-induced cytokine release syndrome (search). The grant represents the second national approval within Poolbeg's CRS patent family, following a ruling by IP Australia in March 2026.
The patent covers the use of any p38 MAPK (search) inhibitor, including POLB 001, for the prevention of immunotherapy-induced CRS, and is supported by proprietary data generated by the company. The application was accelerated through the Patent Prosecution Highway, a mechanism that allows expedited examination in participating countries where a favourable ruling has already been secured elsewhere.
Targeting Life-Threatening Side Effects
POLB 001 is being developed as a potential preventative therapy for cytokine release syndrome (search), a serious and potentially life-threatening immune overreaction triggered by certain cancer (search) immunotherapy treatments. The drug candidate represents a p38 MAPK (search) inhibitor designed to address this significant clinical challenge in cancer care.
Poolbeg filed its initial oncology patent applications in the UK in January 2023 before entering the international Patent Cooperation Treaty system a year later. The company's intellectual property portfolio now spans both cancer (search) immunotherapy-induced CRS and severe influenza across multiple jurisdictions, with further territories under pursuit.
Partnership Appeal and Clinical Progress
Chief executive Jeremy Skillington said the patent enhances POLB 001's appeal to potential partners, particularly ahead of interim data from the TOPICAL trial expected this summer. The TOPICAL trial is investigating POLB 001 as a preventative for CRS in relapsed or refractory multiple myeloma (search) patients.
Poolbeg said the broad agreement with the FDA on the development pathway represents an important milestone that provides potential partners with greater certainty on the route to market, further de-risking the programme. The company believes there is an attractive route to market for POLB 001 and that the FDA feedback reaffirmed the appeal of the programme to potential licensing or development partners.